Pharmacotherapy of dyslipidemia in postmenopausal women: weighing the evidence.
J Womens Health Gend Based Med
; 8(7): 901-17, 1999 Sep.
Article
em En
| MEDLINE
| ID: mdl-10534293
ABSTRACT
In the United States, coronary heart disease (CHD) is the leading cause of death in women. The incidence of CHD rises dramatically in women following menopause, which can be partially attributed to a more atherogenic lipoprotein profile. For years, observational and epidemiological data have suggested that estrogen and progesterone therapy reduced CHD end points. However, the first prospective trial that evaluated hormone replacement therapy (HRT) for secondary CHD prevention demonstrated no positive cardiovascular benefit of HRT compared with placebo. In interventional studies, the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)reductase inhibitors significantly reduced CHD outcomes in postmenopausal women, and these agents have emerged as the drugs of choice for primary and secondary CHD prevention. The selective estrogen receptor modulators (SERMs) may have a role in CHD prevention, but long-term clinical trials evaluating end points are needed. An evidence-based approach is necessary when deciding the appropriate pharmacotherapy of dyslipidemia in postmenopausal women.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Contexto em Saúde:
2_ODS3
/
6_ODS3_enfermedades_notrasmisibles
Problema de saúde:
2_muertes_prematuras_enfermedades_notrasmisibles
/
6_cardiovascular_diseases
/
6_endocrine_disorders
/
6_ischemic_heart_disease
Assunto principal:
Pós-Menopausa
/
Doença das Coronárias
/
Hiperlipidemias
Tipo de estudo:
Clinical_trials
Limite:
Aged
/
Female
/
Humans
/
Middle aged
País/Região como assunto:
America do norte
Idioma:
En
Revista:
J Womens Health Gend Based Med
Assunto da revista:
GINECOLOGIA
/
SAUDE DA MULHER
Ano de publicação:
1999
Tipo de documento:
Article
País de afiliação:
Estados Unidos